Prelude Therapeutics PRLD
NASDAQ PRLD
$3.68 -0.11 (-2.90%)
As of: Oct 2, 2026 · 2:14 PM EDT

Prelude Therapeutics (PRLD) Cash & Equivalents (2019 - 2026)

Updated

Prelude Therapeutics' Cash & Equivalents came in at $155.2 million for Q2 2026, up 420.9% from $29.8 million a year earlier and up 83.0% from the prior quarter.

Analysis

Prelude Therapeutics (PRLD) Cash & Equivalents (2019 - 2026) Analysis & Trends

At the end of FY2025, Prelude Therapeutics' Cash & Equivalents was $38.49 million, up 133.0% from FY2024.

  • Cash & Equivalents carries a five-year compound annual growth rate of -29.3% (FY2020 to FY2025).
  • Going back by year, Cash & Equivalents was $16.52 million in FY2024 (-43.7%), $29.34 million in FY2023 (-15.3%), $34.65 million in FY2022 (-3.4%) and $35.87 million in FY2021 (-83.6%).
  • The Q2 2026 figure represents the highest quarterly Cash & Equivalents since Q2 2021.
  • Year-over-year, Cash & Equivalents has increased for four consecutive quarters, with growth averaging 113.6% over the last eight quarters.
  • The fastest year-over-year change in Cash & Equivalents over five years came in Q2 2026 (growth of 420.9%), and the weakest in Q1 2022 (a decline of 84.7%).
  • Business Quant data shows PRLD's Cash & Equivalents at $84.8 million (Q1 2026), $38.49 million (Q4 2025) and $58.2 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 20.42 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 6.57 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 6.85 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 7.62 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 4.89 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 13.99 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 3.18 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 976.00 Mn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 6.14 Bn
10 Prelude Therapeutics 312.03 Mn -285.27 Mn - 155.20 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 155.20 Mn
Mar 31, 2026 84.80 Mn
Dec 31, 2025 38.49 Mn
Sep 30, 2025 58.20 Mn
Jun 30, 2025 29.80 Mn
Mar 31, 2025 44.31 Mn
Dec 31, 2024 16.52 Mn
Sep 30, 2024 15.18 Mn
Jun 30, 2024 31.87 Mn
Mar 31, 2024 28.75 Mn
Dec 31, 2023 29.34 Mn
Sep 30, 2023 19.94 Mn
Jun 30, 2023 30.49 Mn
Mar 31, 2023 22.25 Mn
Dec 31, 2022 34.65 Mn
Sep 30, 2022 56.07 Mn
Jun 30, 2022 54.75 Mn
Mar 31, 2022 55.68 Mn
Dec 31, 2021 35.87 Mn
Sep 30, 2021 61.42 Mn
API Access

Prelude Therapeutics Cash & Equivalents API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=PRLD&period=max&api_key=YOUR_API_KEY